Trials / Completed
CompletedNCT07020884
A Study of ZT002 Injection With Subjects With Overweight or Obesity
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Subjects With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZT002 Injection | Administered SC |
| DRUG | ZT002 Placebo | Administered SC |
Timeline
- Start date
- 2024-08-14
- Primary completion
- 2025-05-07
- Completion
- 2025-05-29
- First posted
- 2025-06-13
- Last updated
- 2025-12-10
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07020884. Inclusion in this directory is not an endorsement.